Overview

CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events

Status:
Completed

Trial end date:
2004-02-01

Target enrollment:

Participant gender:

Summary

A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy, microalbuminuria, macroalbuminuria, or who currently smoke, but who do not have established corornary heart disease or other macrovascular disease.

Phase:

Phase 4

Details

Lead Sponsor:

Pfizer

Collaborators:

Department of Health, United Kingdom
Diabetes UK

Treatments:

Atorvastatin
Atorvastatin Calcium